Cooley represented the former board of directors of Sequenom in a nearly seven-year-long securities class action brought by former investors in the company. In July 2016,...
In re Sequenom Inc. Stockholder Litigation
ACELYRIN’s $621 Million Initial Public Offering
Cooley advised ACELYRIN, and Davis Polk advised the joint book-running managers. ACELYRIN, INC. announced its upsized initial public offering of 34,500,000 shares of common stock at...
Wong v. Arlo Technologies Inc. et al
Davis Polk represented the underwriters, Cooley represented Arlo and its officers and directors, and Wilson Sonsini represented Netgear. In the California state and federal court securities...
SirionLabs’ Series D Funding Round
Cooley advised Brookfield Growth on the deal. Brookfield Growth, the technology investment arm of Brookfield Asset Management, announced its investment of $25 million in SirionLabs’ Series D...
Amgen’s Acquisition of Horizon Therapeutics
Cooley LLP and Matheson LLP advised Horizon, while Sullivan & Cromwell LLP and William Fry LLP advised Amgen. Debevoise & Plimpton LLP advised JP Morgan. Macfarlanes...
Pfizer’s $6.7 Billion Acquisition of Arena Pharmaceuticals
Ropes & Gray advised Pfizer Inc. in the deal, while Cooley represented Arena Pharmaceuticals. Debevoise & Plimpton advised Evercore Group and Guggenheim Securities as financial advisors...